<?xml version="1.0" encoding="UTF-8"?>
<oaidc:dc xmlns:oaidc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:contributor xsi:type="unistra:Directeur">Gantner, Pierre</dc:contributor>
<dc:coverage xsi:type="unistra:Coverage">FR</dc:coverage>
<dc:creator xsi:type="unistra:Auteur">Brémon, Lucile</dc:creator>
<dc:date xsi:type="unistra:Date">2024-01-31</dc:date>
<dc:description xsi:type="unistra:Discipline" xml:langue="fre">Pharmacie</dc:description>
<dc:description xsi:type="unistra:Resume" xml:langue="fre">Le Virus de l’Immunodéficience Humaine (VIH) est un virus qui s’attaque au système immunitaire des personnes qu’il infecte. Cette atteinte à l’immunité a rendu cette population particulièrement à risque lors de la pandémie de Covid-19, provoquée par le SARS-CoV-2. L’étude SeCoVIHA, lancée en novembre 2020 aux Hôpitaux Universitaires de Strasbourg, a pour but d’observer l’impact du SARS-CoV-2 chez les personnes vivant avec le VIH. Le développement de vaccins dirigés contre ce virus a ainsi permis de développer cette sous-étude, afin d’observer l’efficacité des différents vaccins chez cette population.</dc:description>
<dc:description xsi:type="unistra:Resume" xml:langue="fre">The Human Immunodeficiency Virus (HIV) attacks the immune system of infected people. This population was particularly at risk during the Covid-19 pandemic, caused by the SARS-CoV-2, because of the immunity’s decrease. The SeCoVIHA study, started in November 2020 in the University Hospital of Strasbourg, aims to observe the impact of the SARS-CoV-2 in the people living with HIV. The development of vaccines directed against this virus allowed to develop this sub-study, to observe the efficiency of the different vaccines in this population.</dc:description>
<dc:format xsi:type="dcterms:IMT">PDF</dc:format>
<dc:rights xsi:type="unistra:Droits" xml:lang="fre">Accès libre</dc:rights>
<dc:identifier xsi:type="dcterms:URI">https://publication-theses.unistra.fr/public/theses_exercice/PHA/2024/2024_BREMON_Lucile.pdf</dc:identifier>
<dc:language xsi:type="dcterms:ISO639-2">fr</dc:language>
<dc:source xsi:type="dcterms:URI">http://www.sudoc.fr/276298497</dc:source>
<dc:subject xml:langue="fre">VIH (virus)</dc:subject>
<dc:subject xml:langue="fre">SARS-CoV-2 (virus)</dc:subject>
<dc:subject xml:langue="fre">Vaccination</dc:subject>
<dc:subject xml:langue="fre">VIH</dc:subject>
<dc:subject xml:langue="fre">Covid</dc:subject>
<dc:subject xml:langue="fre">Vaccination</dc:subject>
<dc:subject xml:langue="fre">ARNm</dc:subject>
<dc:subject xml:langue="fre">Traitement antirétroviral</dc:subject>
<dc:subject xml:langue="fre">CD4</dc:subject>
<dc:subject xml:langue="fre">HIV</dc:subject>
<dc:subject xml:langue="fre">Covid</dc:subject>
<dc:subject xml:langue="fre">Vaccination</dc:subject>
<dc:subject xml:langue="fre">mRNA</dc:subject>
<dc:subject xml:langue="fre">Antiretroviral therapy</dc:subject>
<dc:subject xml:langue="fre">CD4</dc:subject>
<dc:subject xml:langue="fre">610</dc:subject>
<dc:title xsi:type="unistra:Titre" xml:lang="fre">Réponse humorale post-vaccinale anti-SARS-CoV-2 chez les personnes vivant avec le VIH</dc:title>
<dc:type xsi:type="unistra:Mention">Thèse d'exercice</dc:type>
<dc:publisher xsi:type="unistra:Composante">Faculté de pharmacie</dc:publisher>
<dc:type xsi:type="unistra:TheseExercice">These d'exercice Unistra</dc:type>
</oaidc:dc>
